Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) was the recipient of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 1,450,000 shares, a decline of 17.1% from the November 15th total of 1,750,000 shares. Based on an average daily volume of 1,300,000 shares, the days-to-cover ratio is currently 1.1 days. Currently, 1.7% of the company's shares are sold short.
CLBT stock traded up $0.41 during trading on Monday, hitting $20.29. 571,074 shares of the company traded hands, compared to its average volume of 1,177,320. Cellebrite DI has a 1 year low of $7.91 and a 1 year high of $21.72. The stock's 50-day simple moving average is $18.93 and its 200 day simple moving average is $15.82. The company has a market cap of $4.18 billion, a PE ratio of -12.83, a P/E/G ratio of 2.71 and a beta of 1.51.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business had revenue of $106.90 million for the quarter, compared to analyst estimates of $102.06 million. During the same period in the prior year, the company posted $0.09 EPS. The company's revenue for the quarter was up 27.0% on a year-over-year basis. Research analysts expect that Cellebrite DI will post 0.32 earnings per share for the current year.
Several equities research analysts have weighed in on the company. Needham & Company LLC upped their target price on Cellebrite DI from $17.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Craig Hallum increased their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. TD Cowen upped their price target on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a research report on Monday, September 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Monday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $20.57.